193 related articles for article (PubMed ID: 31092368)
21. Acute megakaryoblastic leukemia with trisomy 3 and CBFA2T3::GLIS2: A case report.
Gillam J; Catic A; Paulraj P; Dalton J; Lai G; Jackson-Cook C; Turner S; Ferreira-Gonzalez A; Barrie E
Genes Chromosomes Cancer; 2022 Aug; 61(8):491-496. PubMed ID: 35294081
[TBL] [Abstract][Full Text] [Related]
22. Advances in molecular characterization of pediatric acute megakaryoblastic leukemia not associated with Down syndrome; impact on therapy development.
Li J; Kalev-Zylinska ML
Front Cell Dev Biol; 2023; 11():1170622. PubMed ID: 37325571
[TBL] [Abstract][Full Text] [Related]
23. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia.
Gruber TA; Larson Gedman A; Zhang J; Koss CS; Marada S; Ta HQ; Chen SC; Su X; Ogden SK; Dang J; Wu G; Gupta V; Andersson AK; Pounds S; Shi L; Easton J; Barbato MI; Mulder HL; Manne J; Wang J; Rusch M; Ranade S; Ganti R; Parker M; Ma J; Radtke I; Ding L; Cazzaniga G; Biondi A; Kornblau SM; Ravandi F; Kantarjian H; Nimer SD; Döhner K; Döhner H; Ley TJ; Ballerini P; Shurtleff S; Tomizawa D; Adachi S; Hayashi Y; Tawa A; Shih LY; Liang DC; Rubnitz JE; Pui CH; Mardis ER; Wilson RK; Downing JR
Cancer Cell; 2012 Nov; 22(5):683-97. PubMed ID: 23153540
[TBL] [Abstract][Full Text] [Related]
24. Chromosome 7 abnormalities in acute megakaryoblastic leukemia associated with Down syndrome.
Kobayashi K; Usami I; Kubota M; Nishio T; Kakazu N
Cancer Genet Cytogenet; 2005 Apr; 158(2):184-7. PubMed ID: 15796967
[TBL] [Abstract][Full Text] [Related]
25. CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity.
Masetti R; Bertuccio SN; Pession A; Locatelli F
Br J Haematol; 2019 Feb; 184(3):337-347. PubMed ID: 30592296
[TBL] [Abstract][Full Text] [Related]
26. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.
Bourquin JP; Subramanian A; Langebrake C; Reinhardt D; Bernard O; Ballerini P; Baruchel A; Cavé H; Dastugue N; Hasle H; Kaspers GL; Lessard M; Michaux L; Vyas P; van Wering E; Zwaan CM; Golub TR; Orkin SH
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3339-44. PubMed ID: 16492768
[TBL] [Abstract][Full Text] [Related]
27. Review of the cytogenetic changes in acute megakaryoblastic leukemia: one disease or several?
Lu G; Altman AJ; Benn PA
Cancer Genet Cytogenet; 1993 Jun; 67(2):81-9. PubMed ID: 8330276
[TBL] [Abstract][Full Text] [Related]
28. CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216.
Gress V; Roussy M; Boulianne L; Bilodeau M; Cardin S; El-Hachem N; Lisi V; Khakipoor B; Rouette A; Farah A; Théret L; Aubert L; Fatima F; Audemard É; Thibault P; Bonneil É; Chagraoui J; Laramée L; Gendron P; Jouan L; Jammali S; Paré B; Simpson SM; Tran TH; Duval M; Teira P; Bittencourt H; Santiago R; Barabé F; Sauvageau G; Smith MA; Hébert J; Roux PP; Gruber TA; Lavallée VP; Wilhelm BT; Cellot S
Blood Adv; 2024 Jan; 8(1):112-129. PubMed ID: 37729615
[TBL] [Abstract][Full Text] [Related]
29. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models.
Thiollier C; Lopez CK; Gerby B; Ignacimouttou C; Poglio S; Duffourd Y; Guégan J; Rivera-Munoz P; Bluteau O; Mabialah V; Diop M; Wen Q; Petit A; Bauchet AL; Reinhardt D; Bornhauser B; Gautheret D; Lecluse Y; Landman-Parker J; Radford I; Vainchenker W; Dastugue N; de Botton S; Dessen P; Bourquin JP; Crispino JD; Ballerini P; Bernard OA; Pflumio F; Mercher T
J Exp Med; 2012 Oct; 209(11):2017-31. PubMed ID: 23045605
[TBL] [Abstract][Full Text] [Related]
30. Analysis 33 patients of non-DS-AMKL with or without acquired trisomy 21 from multiple centers and compared to 118 AML patients.
Zhang W; Dun J; Li H; Liu J; Chen H; Yu H; Xu J; Zhou F; Qiu Y; Hao J; Hu Q; Wu X
Hematology; 2023 Dec; 28(1):2231731. PubMed ID: 37522469
[TBL] [Abstract][Full Text] [Related]
31. Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.
Xavier AC; Ge Y; Taub JW
J Mol Diagn; 2009 Sep; 11(5):371-80. PubMed ID: 19710397
[TBL] [Abstract][Full Text] [Related]
32. Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.
Masetti R; Bertuccio SN; Astolfi A; Chiarini F; Lonetti A; Indio V; De Luca M; Bandini J; Serravalle S; Franzoni M; Pigazzi M; Martelli AM; Basso G; Locatelli F; Pession A
J Hematol Oncol; 2017 Jan; 10(1):26. PubMed ID: 28109323
[TBL] [Abstract][Full Text] [Related]
33. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Langebrake C; Creutzig U; Reinhardt D
Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study.
Inaba H; Zhou Y; Abla O; Adachi S; Auvrignon A; Beverloo HB; de Bont E; Chang TT; Creutzig U; Dworzak M; Elitzur S; Fynn A; Forestier E; Hasle H; Liang DC; Lee V; Locatelli F; Masetti R; De Moerloose B; Reinhardt D; Rodriguez L; Van Roy N; Shen S; Taga T; Tomizawa D; Yeoh AE; Zimmermann M; Raimondi SC
Blood; 2015 Sep; 126(13):1575-84. PubMed ID: 26215111
[TBL] [Abstract][Full Text] [Related]
35. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A; Roberts I; Norton A; Vyas P
Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
[TBL] [Abstract][Full Text] [Related]
36. Pediatric Acute Megakaryoblastic Leukemia: Multitasking Fusion Proteins and Oncogenic Cooperations.
Lopez CK; Malinge S; Gaudry M; Bernard OA; Mercher T
Trends Cancer; 2017 Sep; 3(9):631-642. PubMed ID: 28867167
[TBL] [Abstract][Full Text] [Related]
37. Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities.
Cardin S; Bilodeau M; Roussy M; Aubert L; Milan T; Jouan L; Rouette A; Laramée L; Gendron P; Duchaine J; Decaluwe H; Spinella JF; Mourad S; Couture F; Sinnett D; Haddad É; Landry JR; Ma J; Humphries RK; Roux PP; Hébert J; Gruber TA; Wilhelm BT; Cellot S
Blood Adv; 2019 Nov; 3(21):3307-3321. PubMed ID: 31698461
[TBL] [Abstract][Full Text] [Related]
38. Acute megakaryoblastic leukemia in Down syndrome.
Hitzler JK
Pediatr Blood Cancer; 2007 Dec; 49(7 Suppl):1066-9. PubMed ID: 17943965
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
[TBL] [Abstract][Full Text] [Related]
40. Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia.
De Marchi F; Araki M; Komatsu N
Expert Rev Hematol; 2019 May; 12(5):285-293. PubMed ID: 30991862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
